The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 20, 2021

Filed:

Jan. 30, 2015
Applicants:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Regents of the University of Minnesota, Minneapolis, MN (US);

Inventors:

Michael P. Fautsch, Rochester, MN (US);

Peter Dosa, Vadnais Heights, MN (US);

Michael A. Walters, Minneapolis, MN (US);

Gunda I. Georg, St. Paul, MN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 311/20 (2006.01); A61K 9/51 (2006.01); C07K 5/062 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 285/24 (2006.01); A61K 31/549 (2006.01); A61K 31/454 (2006.01); A61K 31/4025 (2006.01); A61K 9/00 (2006.01); A61K 31/675 (2006.01); A61K 31/4439 (2006.01); C07D 201/00 (2006.01); A61K 31/353 (2006.01); C07D 311/70 (2006.01); C07D 405/14 (2006.01); C07F 9/6547 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
C07K 5/06026 (2013.01); A61K 9/00 (2013.01); A61K 9/0048 (2013.01); A61K 9/0051 (2013.01); A61K 31/353 (2013.01); A61K 31/4025 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/549 (2013.01); A61K 31/675 (2013.01); C07D 201/00 (2013.01); C07D 285/24 (2013.01); C07D 311/20 (2013.01); C07D 311/70 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07F 9/6547 (2013.01); C07F 9/65586 (2013.01);
Abstract

The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.


Find Patent Forward Citations

Loading…